Connect Biopharma Holdings (CNTB) Cash & Equivalents (2020 - 2026)

Connect Biopharma Holdings has reported Cash & Equivalents for 7 years, with the latest figure at $46.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 3.51% year-over-year to $46.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.0 million (down 3.51% YoY) and the FY2025 annual result came in at $38.3 million, down 50.99% from the prior year.
• Cash & Equivalents rose to $46.0 million in Q1 2026 per CNTB's latest filing, from $38.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $141.4 million in Q2 2022 and troughed at $37.8 million in Q3 2025.
• A 5-year average of $73.2 million and a median of $77.4 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 71.02% in 2022, then jumped 36.57% in 2023.
• Over 5 years, Cash & Equivalents stood at $77.4 million in 2022, then surged by 36.57% to $105.7 million in 2023, then decreased by 25.96% to $78.2 million in 2024, then tumbled by 50.99% to $38.3 million in 2025, then increased by 20.05% to $46.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $46.0 million, $38.3 million, and $37.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.